Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Update

Palvella Therapeutics, Inc. (NASDAQ:PVLA) was the target of a significant growth in short interest in February. As of February 13th, there was short interest totaling 1,674,747 shares, a growth of 22.2% from the January 29th total of 1,370,113 shares. Based on an average daily volume of 305,933 shares, the short-interest ratio is presently 5.5 days. Approximately 17.8% of the shares of the company are sold short. Approximately 17.8% of the shares of the company are sold short. Based on an average daily volume of 305,933 shares, the short-interest ratio is presently 5.5 days.

Insider Activity

In related news, Director George M. Jenkins purchased 4,000 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was purchased at an average cost of $125.00 per share, with a total value of $500,000.00. Following the completion of the acquisition, the director directly owned 187,171 shares in the company, valued at $23,396,375. This trade represents a 2.18% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Elaine J. Heron bought 2,400 shares of Palvella Therapeutics stock in a transaction dated Friday, February 27th. The stock was purchased at an average price of $125.00 per share, with a total value of $300,000.00. Following the purchase, the director directly owned 47,812 shares in the company, valued at approximately $5,976,500. This trade represents a 5.28% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 20.50% of the company’s stock.

Institutional Trading of Palvella Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Group One Trading LLC boosted its stake in Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares in the last quarter. Archer Investment Corp bought a new stake in shares of Palvella Therapeutics in the 3rd quarter worth $28,000. Russell Investments Group Ltd. acquired a new stake in shares of Palvella Therapeutics in the third quarter valued at $36,000. China Universal Asset Management Co. Ltd. bought a new position in Palvella Therapeutics during the fourth quarter valued at about $167,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in Palvella Therapeutics during the second quarter worth about $37,000. Institutional investors own 40.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on PVLA shares. Raymond James Financial reiterated a “strong-buy” rating and set a $193.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Truist Financial set a $210.00 price target on Palvella Therapeutics in a report on Tuesday, February 24th. Craig Hallum started coverage on shares of Palvella Therapeutics in a report on Thursday, December 4th. They set a “buy” rating and a $175.00 price objective on the stock. HC Wainwright lifted their target price on Palvella Therapeutics from $200.00 to $255.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $200.00 price target on shares of Palvella Therapeutics in a research report on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $176.44.

Palvella Therapeutics Price Performance

PVLA traded down $1.10 during trading hours on Tuesday, hitting $131.51. 312,672 shares of the stock were exchanged, compared to its average volume of 329,963. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of -50.00 and a beta of -0.31. The stock has a 50-day simple moving average of $95.00 and a 200-day simple moving average of $81.11. Palvella Therapeutics has a 12 month low of $18.23 and a 12 month high of $151.18.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.